SEARCH

SEARCH BY CITATION

References

  • 1
    Wee A, Ludwig J, Coffey R, La Russo N, Wiesner R. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Path 1985; 16: 719 25.
  • 2
    Broomé U, Olsson R, Lööf L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610 5.
  • 3
    Bergquist A, Glaumann H, Persson B, Broomé U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case control study. Hepatology 1998; 27: 311 6.
  • 4
    Rosen C, Nagorney D, Wiesner R, Coffey R, LaRusso N. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21 5.
  • 5
    Ramage J, Donaghy A, Farrant J, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 865 9.
  • 6
    Hultcrantz R, Olsson R, Danielsson Å et al. A 3-year prospective study on serum tumour markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 669 73.
  • 7
    Martins E, Fleming K, Garrido M, Hine K, Chapman R. Superficial thrombophlebitis, dysplasia, and cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1994; 107: 537 42.
  • 8
    Fleming K, Claussen O, Glaumann H, Bergquist A, Smith D. Biliary dysplasia in primary sclerosing cholangitis as a marker of increased risk of cholangiocarcinoma. Hepatology 1998; 28: A1136.
  • 9
    Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Immunology 1984; 133: 1710 5.
  • 10
    Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456 62.
  • 11
    Que F & Gores G. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996; 110: 1238 43.
  • 12
    Patel T & Gores G. Apoptosis and hepatobiliary disease. Hepatology 1995; 21: 1725 41.
  • 13
    Symonds H, Krall L, Remington L et al. p53-Dependent apoptosis supresses tumor growth and progression in vivo. Cell 1994; 78: 703 11.
  • 14
    Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature 1991; 351: 453 6.
  • 15
    Gannon J, Greaves R, Iggo R, Lane D. Activating mutations in p53 produce a conformational effect. A monoclonal antibody specific for the mutant form. EMBO 1990; 9: 1595 602.
  • 16
    Korsmeyer S. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879 86.
  • 17
    Ahrendt S, Eisenberger C, Yip L et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999; 84: 88 93.DOI: 10.1006/jsre.1999.5615
  • 18
    Wiesner R & La Russo N. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 74: 200 6.
  • 19
    Chapman R, Arborgh B, Rhodes J et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology. Gut 1980; 21: 870 7.
  • 20
    Evans J & Acheson E. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut 1965; 6: 311 24.
  • 21
    Ludwig J, Barham S, La Russo N, Elveback L, Wiesner R, McCall J. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1: 632 40.
  • 22
    Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27: 166 74.
  • 23
    Holzinger F, Z'graggen K, Büchler M. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol 1999; 10: 122 6.
  • 24
    Kozuka S, Tsubone M, Yamaguchi A. Adenomatous residues in cancerous papilla of Vater. Gut 1981; 22: 1031.
  • 25
    Ludwig J, Wahlström H, Batts K, Wiesner R. Papillary bile duct dysplasia in primary sclerosing cholangitis. Gastroenterology 1992; 102: 2134 8.
  • 26
    Greenblatt M, Bennet W, Hollstein M, Harris C. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855 78.
  • 27
    Rizzi P, Ryder S, Portmann B, Ramage J, Naoumov N, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996; 38: 265 8.
  • 28
    Vautier G, Portmann B, Bomford A, Jenkins D, Ryder S. p53 mutations in dysplastic and neoplastic bile duct epithelium in primary sclerosing cholangitis (Abstract P/C07/017). J Hepatol 1998; 28: 128 .
  • 29
    Zhao M & Zimmermann A. Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity. J Clin Pathol 1997; 50: 394 400.
  • 30
    Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995; 21: 1465 8.
  • 31
    Grasl-Kraupp B, Ruttkay-Nedecky B, Müllauer L et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 1997; 25: 906 12.